The Federal Trade Commission may be winding down its ongoing insulin case against the three largest pharmacy benefit managers, as court documents suggest the agency has reached an agreement with Op | The Federal Trade Commission may be winding down its ongoing insulin case against the three largest pharmacy benefit managers, as court docs suggest the agency has reached an agreement with Optum Rx.

Despite steady demand for obesity medications, 49% of payers who do not currently cover GLP-1s for obesity would not do so at any price, a new

UnitedHealth (UNH) Group subsidiaries OptumRx and Emisar Pharma Services and the Federal Trade Commission have reached an agreement that would s...

The Federal Trade Commission may be winding down its ongoing insulin case against the three largest pharmacy benefit managers, as court documents suggest the agency has reached an…